# Study to Compare the Efficacy of Pristinamycin (Pyostacine ®) Versus Amoxicillin in the Treatment of Acute Community Acquired Pneumonia

> **NCT02332577** · PHASE4 · TERMINATED · sponsor: **Sanofi** · enrollment: 161 (actual)

## Conditions studied

- Pneumonia

## Interventions

- **DRUG:** PRISTINAMYCIN XRP7263
- **DRUG:** Amoxicillin
- **DRUG:** Amoxicillin Placebo
- **DRUG:** PRISTINAMYCIN Placebo

## Key facts

- **NCT ID:** NCT02332577
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04-30
- **Primary completion:** 2023-02-20
- **Final completion:** 2023-02-20
- **Target enrollment:** 161 (ACTUAL)
- **Why stopped:** The sponsor stopped the study due to low recruitment with no safety concerns
- **Last updated:** 2023-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02332577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02332577, "Study to Compare the Efficacy of Pristinamycin (Pyostacine ®) Versus Amoxicillin in the Treatment of Acute Community Acquired Pneumonia". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT02332577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*